Showing 1081-1090 of 1614 results for "".
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- Glaucoma Drugs Continue to Battle for Market Sharehttps://modernod.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/Two new glaucoma drugs introduced in the US in 2018 continue to battle for market share. Rhopressa, from Aerie Pharmaceuticals, got out of the gate faster than Vyzulta from Bausch Health. The growth rate for both drugs slowed in the first quarter of 2019, which is normal after a product launch, a
- Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvienhttps://modernod.com/news/alimera-sciences-announces-launch-of-direct-to-patient-marketing-campaign-for-iluvien/2476603/Alimera Sciences announced the launch of a direct-to-patient (DTP) marketing campaign intended to raise awareness and educate patients diagnosed with diabetic macular edema (DME) and their caregivers about the therapeutic and dosing benefits of Iluvien. The campaign will be supported by the websi
- Eric Bernabei Joins Avellino Labs as Chief Sales and Marketing Officerhttps://modernod.com/news/eric-bernabei-joins-avellino-labs-as-chief-sales-and-marketing-officer/2476483/Avellino Labs announced that Eric Bernabei has joined the company as chief sales and marketing officer. Mr. Bernabei, who brings more than 20 years of clinical and commercial ophthalmic experience to the role, will inform and implement the strategic expansion of Avellino Labs’ disruptive genetic
- Improved Premium IOLs Will Drive Growth in the Global IOL Market Over the Next 5 Yearshttps://modernod.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/Innovation in premium lens technology will fuel patient demand in the global IOL market over the next 5 years, according to a Market Scope report. The improved technology will provide better visu
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider
- EU-5 Ophthalmic Market Will Top $10 Billion in 2023https://modernod.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/Market Scope expects growing demand for retinal pharmaceuticals to help manufacturers’ ophthalmic revenues top $10 billion in 2023 in the five largest economies of the European Union. The ophthalmic markets in France, Germany, Italy, Spain, and the UK––the five countries that made up
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o